| Document Date: 2015-05-27 10:14:30
Open Document File Size: 191,40 KBShare Result on Facebook
City Allentown / London / San Diego / / Company Celgene Corporation / AEs / BP / Las Vegas NV / EPO / / Country United States / United Kingdom / / Event FDA Phase / / IndustryTerm placebo / dose / / MedicalCondition TB / hypertension / cardiomyopathy / disease / hypocalcemia / kidney disease / diabetes / Erythropoietin deficiency / renal insufficiency / chronic kidney disease / heart failure / cardiac disease / coronary artery disease / hypersensitivity / Type 2 diabetes mellitus / ESKD-related anemia / Dizziness / end-stage renal disease / exhibit anemia / Anemia / Fishbane S. Anemia / end-stage kidney disease / / MedicalTreatment Peritoneal dialysis / Red blood cell transfusion / Kidney transplant / Hemodialysis / dialysis / renal transplant / / MusicGroup Nausea / / Organization Congress / EPO administration / New York Heart Association / American Society / / Person Nelson Kopyt / Daniel Aversa / John Havill / Jeffrey Kaupke / / Position Hb / high Hb / Rescue Therapy Kidney transplant Stopping Rule Hb / rescue Hb / consecutive Hb / baseline Hb / target Hb / g/dL Hb / predialysis Hb / Major / / Product SC / BP / AUC28d / sotatercept / placebo / study drug / / ProvinceOrState California / / Region Southern Nevada / / Technology pharmacokinetics / ESA / PDF / dialysis / /
SocialTag |
FP661 Long-term Effects of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001 William T. Smith ; John Havill ; Nelson Kopyt ; Jeffrey Kaupke ; Daniel